The Zhitong Finance App learned that Rezera is a biotech company that is about to enter phase III clinical trials to develop oral NLRP3 inhibitors for inflammatory diseases. The company announced its IPO terms on Thursday.

Zhitongcaijing · 2d ago
The Zhitong Finance App learned that Rezera is a biotech company that is about to enter phase III clinical trials to develop oral NLRP3 inhibitors for inflammatory diseases. The company announced its IPO terms on Thursday.